Should Investors Buy or Sell the Vaccinex Patent News?
Vaccinex stock shot up over 20% in pre-market trading on news that the biotech company had secured a patent.The patent will give the company’s lead candidate, pepinemab, some time to be in market without generic competition, should it get approved.Approval is still over a year away, and there isn’t much to move the stock price other than advancement through clinical trials.Penny stocks are always volatile and investors should be concerned about some investors taking profits or cutting losses on such a strong move.5 stocks we like better than VaccinexQ4 2022 hedge fund letters, conferences and ...